Loading...
A Phase II Evaluation of Cediranib in the Treatment of Recurrent or Persistent Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study
PURPOSE: Cediranib is a multi-tyrosine kinase inhibitor targeting vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), and fibroblast growth factor (FGF) receptors. This phase II study was conducted to assess activity and tolerability of single-agent cediranib in recurre...
Saved in:
| Published in: | Gynecol Oncol |
|---|---|
| Main Authors: | , , , , , , , , , , , , , |
| Format: | Artigo |
| Language: | Inglês |
| Published: |
2015
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4642817/ https://ncbi.nlm.nih.gov/pubmed/26186911 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ygyno.2015.07.018 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|